Media
Proactive Investors
Imugene advances clinical programs with strong trial results and Fast Track status for azer-cel in quarter
Proactive
Imugene clears first IV dose level in Phase 1 onCARlytics trial for solid tumours
Proactive Investors
Imugene secures FDA fast track designation for CAR T-cell therapy azer-cel to combat blood cancer
Proactive Investors
Imugene appoints Darren Keamy as CFO and company secretary
Biotech Dispatch
Imugene appoints chief financial officer and company secretary
Proactive Investors
Imugene secures patent protection in India for CF33 oncolytic virotherapy technology
Haematology Republic
CAR T cell lymphoma trial opens for Aussie patients
Proactive Investors
Imugene secures CD19 oncolytic virus patent in China
Stockhead
Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy
Proactive Investors
Imugene’s Phase 1b Azer-cel trial 57% complete response rate
Proactive Investors
Imugene’s $20 million boost and cancer trial updates
Proactive Investors